Contributions of NavboxNiko

Contributions by NavboxNiko, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 5,188 edits includes activity predating the current log.

1. 08:24, 15 Jun 2026 (diff | hist) GenScript Peptides 17,833 ±0 m expand the product-scope row in the infobox
2. 03:49, 1 May 2026 (diff | hist) Qingdao Saber Technology Pharmaceutical 14,592 ±0 add the outbound storefront link, marked nofollow and sponsored per the external-links convention
3. 06:50, 25 Mar 2026 (diff | hist) CagriSema 5,687 ±0 m add the receptor targets to the lead sentence
4. 06:41, 13 Mar 2026 (diff | hist) Peptide stability table 6,886 ±0 expand §The table
5. 10:25, 30 Jan 2026 (diff | hist) List of GLP-1 receptor agonists 3,862 ±0 add the year of first description to each glossary term where known
6. 07:49, 11 Nov 2025 (diff | hist) Peptide harm reduction 4,800 ±0 rm the specific plan recommendation; out of scope
7. 22:03, 12 Oct 2025 (diff | hist) C-peptide 4,400 ±0 typo
8. 09:54, 23 Nov 2024 (diff | hist) Albumin binding half-life extension 3,310 +153 m add the counter-regulatory glucagon point, sourced
9. 10:54, 26 Sep 2024 (diff | hist) Reverse-phase HPLC 3,045 +33 m state that ultraviolet response is not uniform across impurities
10. 13:00, 21 Sep 2024 (diff | hist) SUSTAIN trial programme 2,824 ±0 m add the randomisation ratio
11. 21:04, 3 Sep 2024 (diff | hist) List of GLP-1 receptor agonists 1,884 ±0 m add the category the list itself belongs in
12. 09:00, 23 Aug 2024 (diff | hist) C-peptide 1,892 +1,892 N new article: laboratory medicine, expansion welcome